The table below shows Immunovant, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q2 2025
Q2 2024
Q2 2023
Q2 2022
Q2 2021
Q2 2020
Operating cash flow
-$117.41M
-$76.20M
-$47.37M
-$65.82M
-$21.21M
-$13.80M
Capital expenditure
$0.00
$182.00K
$45.00K
$42.00K
$18.00K
$47.00K
Investing cash flow
$0.00
-$182.00K
-$45.00K
-$42.00K
-$18.00K
-$47.00K
Dividends paid
-
-
-
IMVT operating cash flow (10-K history)
Immunovant, Inc. reported operating cash flow of -$407.31M for fiscal year 2026. That is down 8.4% from -$375.87M in fiscal 2025. Over the 8 fiscal years shown, operating cash flow declined from -$28.55M (FY 2019) to -$407.31M. Figures come from the company's audited annual reports as filed with the SEC.